Every cell neighborhood has its gatekeepers - receptors perched on the surface, checking IDs, letting signals in, keeping riff-raff out. The IL-23 receptor has spent decades building its reputation as exactly that kind of upstanding surface citizen, standing guard on T cells and buzzing in inflammatory signals like a doorman at a very exclusive immune club. So imagine the surprise when researchers caught IL-23R not at the door at all, but inside the building, apparently running the elevator.
A team led by scientists at Princess Margaret Cancer Centre just published a study in Leukemia showing that in acute myeloid leukemia cells, IL-23R has abandoned its post at the cell surface and taken up an entirely new career - indoors, helping cancer cells divide (Duong et al., 2026). If proteins had LinkedIn profiles, this would be the most dramatic career pivot of the year.
The Receptor That Ghosted Its Own Job
Here's what IL-23R is supposed to do: sit on the surface of T cells and help regulate immune activation, particularly of Th17 cells - the inflammatory responders your body deploys against infections (and, unfortunately, sometimes against your own joints and skin) (Wikipedia: Interleukin 23). Pharmaceutical companies have spent billions developing drugs that block IL-23 signaling to treat psoriasis and inflammatory bowel disease. The receptor's day job is well-documented.
What nobody expected was to find IL-23R overexpressed in AML cells and, critically, not even bothering to go to the cell surface. It's like hiring a bouncer who immediately walks past the velvet rope and starts rearranging the furniture.
Moonlighting as a Spindle Wrangler
Using BioID proximity labeling - a technique where you essentially strap a molecular paint sprayer to your protein of interest and see what gets splattered - the researchers identified IL-23R's new coworkers. The top hits? Mitotic spindle proteins. The very machinery that pulls chromosomes apart during cell division.
The team confirmed that IL-23R physically interacts with the mitotic spindle in AML cells through a specific amino acid sequence called the (S/T)x(I/L)P motif. Think of it as a secret handshake that lets IL-23R join the spindle assembly crew. Without it, no handshake, no spindle interaction - the whole arrangement falls apart.
Pull the Receptor, Watch the Chaos
When the researchers genetically knocked out IL-23R in AML cells, things got messy in the most satisfying way possible. Mitotic spindles couldn't form properly. Chromosomes drifted around like confused tourists instead of lining up for orderly separation. Cell division ground to a halt. Leukemia stem cells and progenitors lost their ability to self-renew. The cells, unable to complete their most basic reproductive task, simply died.
And here's the part that makes this genuinely exciting rather than just scientifically interesting: normal blood-forming cells didn't care. Knock out IL-23R in healthy hematopoietic cells and progenitors, and they shrug it off. They apparently never needed this intracellular side hustle in the first place.
That selectivity - toxic to leukemia, harmless to normal cells - is the white whale of cancer therapy. Most anti-mitotic drugs (taxanes, vinca alkaloids, the various kinase inhibitors that have cycled through clinical trials) hit dividing cells indiscriminately, which is why chemotherapy comes with the side effect profile of a small natural disaster (Komlodi-Pasztor et al., J Cell Biol, 2012). A target that's only essential in cancer cells? That's the whole point of the last two decades of precision oncology.
Why This Matters Beyond the Bench
AML remains one of the most stubborn blood cancers to treat. Five-year survival rates hover around 30%, worse in older adults. Relapse is common, and the genetic complexity of the disease means that what works for one patient's leukemia may be useless for another's (Kantarjian et al., Am J Hematol, 2025). The field desperately needs new targets, especially ones that don't require the patient's bone marrow to be collateral damage.
IL-23R's intracellular moonlighting also raises a broader question that should keep cell biologists up at night: how many other "well-characterized" surface receptors are secretly holding down second jobs inside cancer cells? The assumption that a receptor does what it does on the cell surface, and nothing else, just got a lot less comfortable. A recent review cataloging IL-23R's unexpected connections to multiple cancer types suggests this rabbit hole goes deep (Ferrara et al., Cancers, 2024).
For now, the next steps are clear: figure out whether you can drug the (S/T)x(I/L)P motif interaction, test whether this holds up across the genetic zoo of AML subtypes, and see if other leukemias share this vulnerability. The doorman moved inside. The question is whether we can lock him out for good.
References
-
Duong N, Khan DH, Thomas GE, et al. Intracellular IL-23R is necessary for mitotic spindle formation and viability in AML. Leukemia. 2026. DOI: 10.1038/s41375-026-02949-8. PMID: 41998300.
-
Ferrara G, et al. The IL-23R and Its Genetic Variants: A Hitherto Unforeseen Bridge Between the Immune System and Cancer Development. Cancers. 2024;17(1):55. DOI: 10.3390/cancers17010055. PMCID: PMC11718844.
-
Kantarjian H, et al. Acute Myeloid Leukemia: 2025 Update on Diagnosis, Risk-Stratification, and Management. Am J Hematol. 2025. DOI: 10.1002/ajh.27625. PMID: 39936576.
-
Komlodi-Pasztor E, Sackett DL, Bhatt AS. Anti-mitotic therapies in cancer. J Cell Biol. 2012;218(1):10-11. DOI: 10.1083/jcb.201111031.
-
Oppmann B, et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity. 2000;13(5):715-725. DOI: 10.1016/S1074-7613(00)00070-4.
Disclaimer: The image accompanying this article is for illustrative purposes only and does not depict actual experimental results, data, or biological mechanisms.